These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24390246)

  • 1. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
    Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
    Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.
    Jager NG; Rosing H; Schellens JH; Beijnen JH; Linn SC
    Breast Cancer Res Treat; 2014 Jul; 146(1):137-44. PubMed ID: 24859000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
    Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
    Antunes MV; Raymundo S; de Oliveira V; Staudt DE; Gössling G; Peteffi GP; Biazús JV; Cavalheiro JA; Tre-Hardy M; Capron A; Haufroid V; Wallemacq P; Schwartsmann G; Linden R
    Talanta; 2015 Jan; 132():775-84. PubMed ID: 25476377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
    Teunissen SF; Jager NG; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1677-85. PubMed ID: 21543272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.
    de Krou S; Rosing H; Nuijen B; Schellens JH; Beijnen JH
    Ther Drug Monit; 2017 Apr; 39(2):132-137. PubMed ID: 28045782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
    Arellano C; Allal B; Goubaa A; Roché H; Chatelut E
    J Pharm Biomed Anal; 2014 Nov; 100():254-261. PubMed ID: 25173109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of tamoxifen using LC-MS/MS.
    Tchu SM; Lynch KL; Wu AH
    Methods Mol Biol; 2012; 902():211-22. PubMed ID: 22767121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
    Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
    Welzen ME; Dezentjé VO; van Schaik RH; Colbers AP; Guchelaar HJ; van Erp NP; den Hartigh J; Burger DM; van Laarhoven HW
    Ther Drug Monit; 2015 Aug; 37(4):501-7. PubMed ID: 26192892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
    Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally administered endoxifen is a new therapeutic agent for breast cancer.
    Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
    Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients.
    Maggadani BP; Harmita ; Haryono SJ; Rinaldi MR; Harahap Y
    Drug Des Devel Ther; 2021; 15():2417-2430. PubMed ID: 34113081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
    Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
    Sanchez-Spitman AB; Moes DAR; Swen JJ; Dezentjé VO; Lambrechts D; Neven P; Gelderblom H; Guchelaar HJ
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1141-1152. PubMed ID: 32468081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-performance liquid chromatography method with fluorescence detection for the routine quantification of tamoxifen, endoxifen and 4-hydroxytamoxifen in plasma from breast cancer patients.
    Rangel-Méndez JA; Graniel-Sabido MJ; Sánchez-Cruz JF; Moo-Puc R
    Biomed Chromatogr; 2019 Apr; 33(4):e4462. PubMed ID: 30536934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma.
    Antunes MV; Rosa DD; Viana Tdos S; Andreolla H; Fontanive TO; Linden R
    J Pharm Biomed Anal; 2013 Mar; 76():13-20. PubMed ID: 23291438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.